<prompt> Answer this question truthfullyWhat medical treatment is recommended for large cell lung carcinoma?  <response>: <reason> Initial chemotherapy for patients with large cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging. Chemotherapy for patients with large cell carcinoma of the lung, is divided into 2 main types: Specific-inhibitor therapy usually indicated with the presence of a genetic mutation. Platinum-based chemotherapy usually indicated with the absence of a genetic mutation. Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung. Erlotinib is the first-line treatment for patients with large cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor EGFR mutations.Platinum-based chemotherapy cisplatin, carboplatin, etoposide, irinotecan are the mainstay of large cell carcinoma of the lung Platinum-based chemotherapy consists of four to six cycles Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent Chemotherapy treatments for large cell carcinoma of the lung, include: Preferred regimen 1: Cisplatin 50 mgm2 days 1 and 8 and vinorelbine 25 mgm2 days 1, 8, 15, 22, every 28 days for 4 cycles. Preferred regimen 2: Cisplatin 100 mgm2 day 1 and vinorelbine 30 mgm2 days 1, 8, 15, 22, every 28 days for 4 cycles. Preferred regimen 3: Cisplatin 75-80 mgm2 day 1 and vinorelbine 25-30 mgm2 days 1 8, every 21 days for 4 cycles. Preferred regimen 4: Cisplatin 100 mgm2 day 1 and etoposide 100 mgm2 days 1-3, every 28 days for 4 cycles. Preferred regimen 5: Cisplatin 80 mgm2 days 1, 22, 43, 64 and vinblastine 4 mgm2 days 1, 8, 15, 22, 29 then every 2 wks after day 43, every 21 days for 4 cycles. Preferred regimen 6: Cisplatin 75 mgm2 day 1 and gemcitabine 1250 mgm2 days 1, 8, every 21 days for 4 cycles. Preferred regimen 7: Cisplatin 75 mgm2 day 1 and docetaxel 75 mgm2 day 1, every 21 days for 4 cycles. Preferred regimen 8: Cisplatin 75 mgm2 day 1 and pemetrexed 500 mgm2 day 1 for nonsquamous without specific histologic subtype, every 21 days for 4 cycles.Preferred regimen 1: Paclitaxel 200 mgm2 day 1, carboplatin AUC 6 day 1, every 21 days. Preferred regimen 1: Cisplatin 50 mgm2 on days 1, 8, 29, and 36 and etoposide 50 mgm2 days 1-5, 29-33 with concurrent thoracic radiation therapy. Preferred regimen 2: Cisplatin 100 mgm2 days 1 and 29 and vinblastine 5 mgm2weekly x 5 with concurrent thoracic radiation therapy. Preferred regimen 3: Carboplatin AUC 5 on day 1 and pemetrexed 500 mgm2 on day 1 every 21 days for 4 cycles with concurrent thoracic radiation therapy. Preferred regimen 4: Cisplatin 75 mgm2 on day 1 and pemetrexed 500 mgm2 on day 1 every 21 days for 3 cycles with concurrent thoracic radiation therapy.Preferred regimen 1: Cisplatin 100 mgm2 on days 1 and 29 and vinblastine 5 mgm2weekly on days 1, 8, 15, 22, and 29 followed by radiation therapy. Preferred regimen 2: Paclitaxel 200 mgm2 over 3 hours on day 1 and carboplatin AUC 6 over 60 minutes on day 1 every 3 weeks for 2 cycles followed by thoracic radiation therapy. Preferred regimen 1: Paclitaxel 45-50 mgm2 weekly and carboplatin AUC 2 with concurrent thoracic radiation therapy followed by 2 cycles of paclitaxel 200 mgm2 and carboplatin AUC 6. Preferred regimen 2: Cisplatin 50 mgm2 on days 1, 8, 29, and 36 and etoposide 50 mgm2 days 1-5, 29-33 with concurrent thoracic radiation therapy followed by cisplatin 50 mgm2 and etoposide 50 mgm2 x 2. 